Clinical Trials in Italy — Country Dashboard | 3,692 EU Studies

Filter these 3,692 trials by condition, phase, sponsor and more.

Open in Search →

3,692 Registered trials

1,496 Recruiting

1,850 Completed trials

891 Sponsors active

776 Research sites

Phase III

Phase II

Phase III: 1649 Phase II/III: 155 Phase II: 1117 Phase I/II: 212 Phase III/IV: 28 Phase IV: 153 Phase I: 119 Phase I (Other): 111 Phase I (FiH): 142 Other: 5 Other: 1

Oversight events in trials active here:

107 serious breaches 827 temporary halts 64 urgent safety measures 84 unexpected events 162 corrective measures across 455 trials

View oversight register →

Top conditions

Non-small cell lung cancer 135 Non-small cell lung cancer metastatic 50 Ovarian cancer 32 Diffuse large B-cell lymphoma 27 Breast cancer 27 Crohn's disease 26 Colorectal cancer 26 Endometrial cancer 25 Prostate cancer metastatic 23 Myasthenia gravis 22 Systemic lupus erythematosus 22 Asthma 20

Top sponsors

Merck Sharp & Dohme LLC 180 AstraZeneca AB 160 Novartis Pharma AG 145 F. Hoffmann-La Roche AG 139 Janssen - Cilag International 93 AbbVie Deutschland GmbH & Co. KG 89 Sanofi-Aventis Recherche & Developpement 76 Bristol-Myers Squibb Services Unlimited Company 65 Pfizer Inc. 64 Amgen Inc. 60 Glaxosmithkline Research & Development Limited 60 Boehringer Ingelheim International GmbH 50

Cities with most trials

All 250 cities →

All trials — page 106

3,692 total

Study BT8009-100 in Patients with Nectin-4 Expressing Advanced Malignancies. Ended

2023-509781-37-00 Phase I (FiH) Nectin-4 Expressing Advanced Malignancies. Bicycletx Limited
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexande… Ended

2024-510603-11-00 Phase I (FiH) Alexander Disease Ionis Pharmaceuticals Inc.
A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac… Ended

2024-514467-26-00 Phase II Indolent Systemic Mastocytosis Telios Pharma Inc.
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Phase III Non-alcoholic steatohepatitis (NASH) Novo Nordisk A/S
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Phase III Diffuse Large B-Cell Lymphoma (DLBCL) ADC Therapeutics S.A.
Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel… Ended

2024-511637-35-00 Phase III Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) Fondazione Italiana Linfomi Ets
Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Ended

2024-518909-18-00 Phase III HIV-1 infected individuals currently taking an INSTI-based t… Societa Italiana Di Malattie Infettive E Tropicali SIMIT
Inebilizumab efficacy and safety in adults with myasthenia gravis Ended

2023-510006-40-00 Phase III Myasthenia Gravis which is either due to acetylcholine recep… Horizon Therapeutics Ireland Designated Activity Company
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo… Ended

2023-506526-37-00 Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) F. Hoffmann-La Roche AG
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended

2024-516632-99-00 Phase II Advanced (stage III B-C-IV) ovarian, primary peritoneal and … Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Phase II Solid tumors F. Hoffmann-La Roche AG
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended

2023-505835-11-00 Phase III Chronic Migraine Eli Lilly & Co.
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended

2023-505836-36-00 Phase III Migraine Eli Lilly & Co.
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12… Ended

2023-505964-13-00 Phase III Hemophilia A F. Hoffmann-La Roche AG
A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended

2022-502705-15-00 Phase III High-risk muscle-invasive bladder cancer F. Hoffmann-La Roche AG
A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in pat… Ended

2023-507695-52-00 Phase III Mantle cell lymphoma Loxo Oncology Inc.
A Study of Osimertinib with or without Chemotherapy versus Chemotherapy alone as neoadjuvant therapy for Patients with Epidermal Growth Fact… Ended

2022-502606-33-00 Phase III Patients with histologically or cytologically documented non… AstraZeneca AB
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juven… Ended

2023-507184-19-00 Phase III Juvenile Psoriatic Arthritis  Enthesitis Related Arthritis Eli Lilly & Co.
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended

2023-507890-17-00 Phase III Anemia associated with myeloproliferative neoplasm (MPN)-ass… Celgene Corp.
Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended

2024-512354-21-00 Phase II Newly diagnosed multiple myeloma Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Phase III Colorectal cancer (BRAF V600E-mutant mCRC) Pfizer Inc.
CD19-CAR_Lenti in pediatric patients affected by relapsed/refractory B-ALL or aggressive B-NHL Ended

2024-519174-39-00 Phase I (FiH) Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and D… Ospedale Pediatrico Bambino Gesu
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended

2022-503072-84-00 Phase III stage IIIa cardiac AL amyloidosis Alexion Pharmaceuticals Inc.
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended

2022-503073-11-00 Phase III Stage IIIb cardiac AL amyloidosis Alexion Pharmaceuticals Inc.

Showing 2,521–2,544 of 3,692 trials

← All countries